FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and TherapyLucie C. Kompier, Ellen C. Zwarthoff, Irene Lurkin et al.|PLoS ONE|2010Cited by 314
Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic MarkersRaju Kandimalla, Ellen C. Zwarthoff, Angela A.G. van Tilborg et al.|European Urology|2012Cited by 106
The development of multiple bladder tumour recurrences in relation to the <i>FGFR3</i> mutation status of the primary tumourLucie C. Kompier, Ellen C. Zwarthoff, Marcel Vermeij et al.|The Journal of Pathology|2008Cited by 49
<i>FGFR3</i> Mutation Analysis in Voided Urine Samples to Decrease Cystoscopies and Cost in Nonmuscle Invasive Bladder Cancer Surveillance: A Comparison of 3 StrategiesKim E.M. van Kessel, Ewout W. Steyerberg, Lucie C. Kompier et al.|The Journal of Urology|2012Cited by 33
Selection of Microsatellite Markers for Bladder Cancer Diagnosis without the Need for Corresponding BloodAngela A.G. van Tilborg, Ellen C. Zwarthoff, Lucie C. Kompier et al.|PLoS ONE|2012Cited by 17